letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12345678910111213...99100»
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Journal:  Ribociclib-induced autoimmune-like hepatitis: a case report. (Pubmed Central) -  Nov 29, 2024   
    Managed with prednisolone and azathioprine, ribociclib was reintroduced at a reduced dose and later escalated to full dose. This case report highlights the importance of a multidisciplinary approach to balance oncologic efficacy with hepatologic safety.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Journal, Metastases:  Abemaciclib and Letrozole in Metastatic Male Breast Cancer. (Pubmed Central) -  Nov 19, 2024   
    Letrozole FET could be a better alternative to the conventional HRT cycles, in selected population of patients, in terms of reproductive outcomes and patient satisfaction. In summary, this case report clearly shows the effectiveness of the therapeutic approach and should be discussed for the treatment of future patients.
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Journal:  Case report: Efficacy of later-line fam-trastuzumab deruxtecan in a patient with triple-positive breast cancer with brain metastases. (Pubmed Central) -  Nov 19, 2024   
    The patient then received capecitabine, neratinib, GnRH agonist, and letrozole; however, her brain metastases still progressed after 7 months...Now aged 30, the patient is continuing to receive T-DXd treatment to prevent recurrence. We conclude that T-DXd was effective for the treatment of brain metastases in this young patient with triple-positive metastatic breast cancer who had multiple risk factors and had received several anti-HER2 therapies prior to T-DXd.
  • ||||||||||  Trial initiation date:  SWE-Switch: Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer (clinicaltrials.gov) -  Nov 19, 2024   
    P3,  N=3832, Not yet recruiting, 
    We conclude that T-DXd was effective for the treatment of brain metastases in this young patient with triple-positive metastatic breast cancer who had multiple risk factors and had received several anti-HER2 therapies prior to T-DXd. Initiation date: May 2024 --> Jan 2025
  • ||||||||||  letrozole / Generic mfg.
    Reproductive Outcome after Metroplasty of T-Shaped Uterus in Infertile Patients (Exhibit Hall; Virtual) -  Nov 17, 2024 - Abstract #AAGL2024AAGL_820;    
    Depending on the underling etiology, couples were offered to try to conceive naturally, with fertility medication (Letrozole), intrauterine insemination after controlled ovarian stimulation, or in vitro fertilization... This pilot study suggests that hysteroscopic metroplasty of T-shaped uterus with septoplasty, if PSU is found, may improve reproductive outcome in infertile patients and those with infertility and RPL.
  • ||||||||||  pentylenetetrazole (BTD-001) / Balance Therap
    Preclinical, Journal:  Hyperandrogenism Decreases Seizure Threshold in A Rat Model of Polycystic Ovary Syndrome. (Pubmed Central) -  Nov 13, 2024   
    This study delves into the impact of elevated androgen levels on seizure threshold, providing crucial insights into the underpinnings of the comorbidity between PCOS and epilepsy. These findings significantly contribute to the evolving field of epilepsy research, emphasizing the imperative consideration of hormonal influences for the development of targeted therapeutic interventions in individuals with epilepsy and PCOS.
  • ||||||||||  AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER () -  Nov 9, 2024 - Abstract #CTOS2024CTOS_601;    
    Combination therapies (GnRHa plus L or S plus L) seem to be valuable alternatives in the 2L setting but more investigations are needed in this scenario. Furthermore, basing on our data, no recommendation about safe interruption of hormonal treatment can be made.To this end, we encourage data sharing between referral centers and suggest to perform a thorough pathological characterization of hormone receptors expression in AA tissue specimens, including AR in all pts, in order to potentially identify predictive factors of treatment sensitivity.
  • ||||||||||  zotatifin (eFT226) / eFFECTOR Therap, Verzenio (abemaciclib) / Eli Lilly
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) -  Nov 7, 2024   
    P2,  N=130, Active, not recruiting, 
    In conclusion, our case report described successful oocytes cryopreservation, without changes in the appearance of ovarian cysts, in nulliparous women with early-stage SBOT who underwent OS with simultaneous administration of letrozole. Recruiting --> Active, not recruiting | Trial completion date: Aug 2029 --> Aug 2030 | Trial primary completion date: Aug 2026 --> Aug 2027
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Ibrance (palbociclib) / Pfizer
    Trial primary completion date, Metastases:  PALVEN: Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (clinicaltrials.gov) -  Nov 7, 2024   
    P1,  N=17, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Aug 2029 --> Aug 2030 | Trial primary completion date: Aug 2026 --> Aug 2027 Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Enrollment closed, Trial primary completion date:  TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (clinicaltrials.gov) -  Nov 6, 2024   
    P2,  N=90, Active, not recruiting, 
    Trial primary completion date: Jun 2024 --> Jun 2025 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> Jun 2025
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Can letrozole be repurposed for the treatment of visceral leishmaniasis? (Pubmed Central) -  Nov 6, 2024   
    In addition, the proportion of developing granulomas decreased and that of mature granulomas increased in the liver, while there was no significant change in organ architecture in the spleen. Based on these data, repositioning of LET may be promising for the treatment of visceral leishmaniasis in humans.
  • ||||||||||  letrozole / Generic mfg.
    Central airway obstruction as initial presentation of metastasis from breast cancer () -  Nov 5, 2024 - Abstract #APSR2024APSR_390;    
    Introduction: Breast cancer (BC) metastasis accounts for the majority of breast cancer deaths and patients still have a risk of recurrence with rates of 23% and 38% by five and 25 years after diagnosis.1 BC metastasis presenting as a solitary mediastinal tumor is uncommon.1 Case Report: In this report, we present a case of a 70 year old female known case of Bronchial asthma and Breast Cancer Stage IIIB who underwent modified radical mastectomy in 2015 and maintained on Letrozole 2.5 mg/tab 1 tablet once a day since 2023...Approach to management should prioritize biopsy to determine subsequent management. For this case, the mass is causing an extrinsic airway obstruction, local management in the form of radiation therapy was indicated.
  • ||||||||||  Economic Impact of a Pharmacotherapeutic Management Program for Oncological Patients () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1723;    
    The drugs associated were mainly letrozole 9.5%, anastrozole 8.8%, capecitabine 8%, abiraterone 6.1%, temozolamide 4.6% and lenalidomide 4.6%. Clinical follow-up and pharmacotherapeutic management in oncology patients allow for obtaining satisfactory clinical results and a significant economic impact on the health system.
  • ||||||||||  Observational data, Retrospective data, Journal:  Initiation of Oral Endocrine Therapy and Survival Benefit Among Women with Early-Stage Breast Cancer. (Pubmed Central) -  Nov 4, 2024   
    ET initiation and adherence was associated with reduced risk of all-cause (adjusted HR = 0.62, 0.59-0.66; HR = 0.55, 0.53-0.59; respectively) and breast cancer related (adjusted HR = 0.57, 0.50-0.64; HR = 0.41, 0.36-0.47; respectively) mortality compared with noninitiators. Women with early-stage breast cancer who initiate ET and are adherent to treatment may achieve survival benefits compared with noninitiators.